<DOC>
	<DOCNO>NCT01342679</DOCNO>
	<brief_summary>The purpose study evaluate complete molecular response Dasatinib patient Philadelphia chromosome-positive chronic myeloid leukemia</brief_summary>
	<brief_title>A Study Complete Molecular Response Chronic Myeloid Leukemia Chronic Phase Patients , Treated With Dasatinib</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Chronic Myeloid Leukemia Chronic Phase 20 year old ECOG performance status ( PS ) score 02 Patients major molecular response ( MMR ) CMR Adequate organ function ( hepatic , renal lung ) Signed write informed consent A case double cancer activity Women pregnant breastfeed The case Pleural effusion clearly Patients complication history severe uncontrolled cardiovascular failure follow Myocardial infarction within 6 month Angina within 3 month Congestive heart failure within 3 month suspect congenital QT syndrome QTc interval 450msec baseline A serious uncontrolled medical disorder would impair ability subject receive protocol therapy Prior treatment dasatinib Subjects T315I , F317L V299L BCRABL point mutation</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>chronic myeloid leukemia</keyword>
	<keyword>dasatinib</keyword>
	<keyword>complete molecular response</keyword>
</DOC>